Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of HMI-115 in Women With Moderate to Severe Endometriosis-Associated Pain Over a 12-Week Treatment Period

Next Previous
Trial Profile

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of HMI-115 in Women With Moderate to Severe Endometriosis-Associated Pain Over a 12-Week Treatment Period

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BAY 1158061 (Primary)
  • Indications Endometriosis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Hope Medicine

Most Recent Events

  • 24 Oct 2024 According to a Hope Medicine media release, company announces positive results from this trial and in the coming months, company plans to hold End-of-Phase 2 meetings with FDA, NMPA, and other key regulatory authorities to determine next steps for the development of HMI-115.
  • 24 Oct 2024 Interim results (from first 102 patients) published in the Media Release
  • 26 Oct 2023 According to a chimes biologics media release, Hope Medicine has now completed patient enrollment and dosing at all clinical trial centers in the US

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top